Pipeline news
-
19 November 2020
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions.
-
Clearside Biomedical Announces Third Quarter 2020 Financial Results and Provides Corporate Update
11 November 2020
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the third quarter ended September 30, 2020 and provided a corporate update on key initiatives.
-
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara Duncan
06 November 2020
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of itsAtea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the appointment of Barbara Duncan to its Board of Directors, where she will also serve as Chair of the Audit Committee. common stock at a price to the public of $24.00 per share.
-
02 November 2020
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the third quarter ended September 30, 2020 . In addition, the Company provided a clinical and business update.
-
Atea Pharmaceuticals Announces Pricing of Initial Public Offering
29 October 2020
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced the pricing of its initial public offering of 12,500,000 shares of its common stock at a price to the public of $24.00 per share.
-
29 October 2020
Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing.
-
27 October 2020
Wellfleet Insurance has teamed up with binx health to offer college clients access to easy at-home/in-dorm sample collection for COVID-19 testing using binx’s enterprise solutions for population health screening.
-
FDA Grants EUAs for Wren Labs, P23 Coronavirus Tests, Binx Health At-Home Sample Collection Kit
26 October 2020
The US Food and Drug Administration on Tuesday reissued Emergency Use Authorizations for SARS-CoV-2 tests developed by Wren Laboratories and P23 Labs to allow their use with new specimen types, and granted EUA to Binx Health's SARS-CoV-2 at-home nasal swab collection kit.
-
22 October 2020
Atea Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announces that the company has entered into an agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the exclusive rights to research, develop and distribute AT-527 as an oral antiviral treatment for COVID-19 in territories outside of the United States. Under the terms of the agreement, Atea will receive an upfront payment of $350 million in cash from Roche with the potential for future milestone payments and royalties.
-
Marinus Provides Corporate Update on Phase 3 RAISE Trial in Status Epilepticus (SE)
24 September 2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it has satisfied the FDA’s protocol-specific questions for the registrational Phase 3 trial (the RAISE trial) in refractory status epilepticus (RSE), allowing the company to begin enrollment in this clinical trial.
